Beyond The Diagnosis: How IQVIA Biotech Is Transforming Pulmonary Arterial Hypertension Trials For Patient-Centric Care

By Nicole Zandy, Senior Director, Cardiovascular, Renal & Metabolic Therapeutic Area, and Scott Oakes, Senior Director, Emerging Biopharma Operations

Pulmonary arterial hypertension (PAH) remains one of the most challenging conditions to study, with complex pathophysiology, small patient populations, and high variability in disease progression. Traditional trial designs often fall short of addressing these realities, creating barriers to enrollment and slowing innovation.

A patient-centric approach is essential — one that prioritizes accessibility, reduces burden, and leverages advanced tools to capture meaningful outcomes. Strategies such as decentralized trial models, digital health technologies, and real-world data integration can transform recruitment and retention while improving the quality of evidence. Equally important is fostering strong site relationships and multidisciplinary collaboration to ensure consistency in care and data collection.

By rethinking trial design and execution, sponsors can accelerate timelines and deliver therapies that truly meet patient needs. Access the full resource to explore how innovative, patient-focused strategies are reshaping PAH clinical development and driving better outcomes.